NewBiologix
PrivateLast Round
Series A
May 11, 2023
Total Funding Raised
$50M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NewBiologix operates in Healthcare & Life Sciences and is based in Epalinges. Its latest recorded funding round was a Series A round in May 2023.
NewBiologix is a biotechnology company that develops a DNA integration platform for the advanced engineering of cell lines used in gene and cell therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NewBiologix Comparables
Compare NewBiologix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 64x Bio | 87% | |
| Asimov | 84% | |
| Agathos Biologics | 77% |
For institutional investors. Book with your work email.
NewBiologix Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 6, representing 24% of headcount.
- Apr 17, 2026
Monthly visitors grew 136% MoM, reaching 2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 2, 2026
NewBiologix SA is developing Xcell(TM), which replaces repeated transient transfection with genetically engineered, stable producer cell lines for reproducible and scalable rAAV manufacturing, under an agreement supporting Synastra's DMD gene therapy candidate in Switzerland on Sep 2nd '26.
- is_developingSep 2, 2026
NewBiologix SA agrees with Synastra Biotechnology Inc. to develop a stable producer cell line for Synastra's investigational Duchenne muscular dystrophy gene therapy program in Switzerland, using its Xcell Stable Manufacturing Platform to generate and characterize a stable Research Cell Bank on Sep 2nd '26.
For institutional investors. Book with your work email.
NewBiologix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NewBiologix's valuation, stock price, and market status.
Is NewBiologix a public or private company?
NewBiologix is a private company.
What is the current stock price of NewBiologix?
NewBiologix is a private company, so its shares have no public market price. Caplight tracks NewBiologix's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NewBiologix worth (valuation)?
Valuation information for NewBiologix is not publicly available.
Can I buy NewBiologix stock?
NewBiologix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NewBiologix's last funding round?
NewBiologix's most recent funding round was Series A on May 11, 2023.
Who are the main investors in NewBiologix?
Investor information for NewBiologix is not publicly disclosed.
Will NewBiologix IPO soon?
No public IPO plans have been announced for NewBiologix.
How can I track NewBiologix secondary market activity?
Caplight tracks bids, offers, and trades in NewBiologix's shares on secondary markets.